Label effects that can feel like fog
Because brain fog is not a term used in adverse event coding, the useful question is which listed reactions overlap with it. In the US label, four stand out, and their rates differ between the 2.4 mg and 7.2 mg trials. [1]
| Reaction | Adults, 2.4 mg pool: Wegovy® vs placebo | 7.2 mg trials: 7.2 mg / 2.4 mg / placebo |
|---|---|---|
| Fatigue (includes weakness) [1] | 11% vs 5% | 11% / 9% / 5% |
| Dizziness (7.2 mg row includes dizziness on standing) [1] | 8% vs 4% | 6% / 5% / 1% |
| Low blood pressure-related reactions [1] | 1.3% vs 0.4% | — |
| Low blood sugar under 54 mg/dL, type 2 diabetes trial [1] | 6.2% vs 2.5% | — |
What the EU and Canadian documents add
The EU summary of product characteristics lists fatigue as very common and dizziness as common, both mainly during dose escalation. [2] Its section on driving says semaglutide has no or negligible influence on the ability to drive, but that dizziness can occur, mostly while the dose is being raised, and that driving should be done cautiously if it does. [2]
Both the EU leaflet and the Canadian patient information spell out low blood sugar warning signs in more detail than the US guide: feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating, changes in vision and shaking. [2][3] The US Medication Guide lists confusion or drowsiness, slurred speech, blurred vision and weakness among its signs. [1]
Research on thinking and memory
A retrospective cohort drawn from US electronic health records compared people with type 2 diabetes who started semaglutide with matched groups starting sitagliptin, empagliflozin or glipizide. Over 12 months, semaglutide was not linked with higher risk of any of 22 neurological and psychiatric outcomes. It was linked with a lower risk of a recorded cognitive deficit compared with sitagliptin and with glipizide, both with a hazard ratio of 0.72. [4]
This does not prove a protective effect. The study was observational and exploratory, it used diagnoses recorded by clinicians rather than tests of day-to-day sharpness, and it involved diabetes doses rather than Wegovy®. [4] It also cannot capture the short, subtle fogginess people describe in the first weeks of a new dose.
Three layers of explanation
- Supported by the label: tiredness and dizziness were more frequent on Wegovy®, gastrointestinal reactions peaked during dose escalation, and fluid loss from vomiting or diarrhea is linked in the label to low blood pressure and kidney problems. [1] Each of these can make thinking feel slower.
- For people with type 2 diabetes: low blood sugar is more likely when Wegovy® is combined with insulin or a sulfonylurea, and confusion is one of its signs. [1] Outside diabetes, the label notes hypoglycemia has been reported with GLP-1 medicines, but its weight trials did not systematically capture it. [1]
- Proposed but not measured: eating much less could leave gaps in nutrition, and Cleveland Clinic lists poor nutrition among causes of brain fog. [5] No Wegovy® study has tested this link.
Common causes that have nothing to do with the pen
Cleveland Clinic lists lack of sleep, stress, anxiety and depression, hormonal changes in pregnancy or menopause, diabetes and low blood sugar, autoimmune conditions, and recovery from infections such as COVID-19 as frequent causes of brain fog. [5] Several of these are common in the same years of life when people start weight-management treatment.
If the fog came with poor sleep, a stressful period or a new medicine, those deserve as much attention as the injection.
What helps, according to the sources
Cleveland Clinic says there is no specific treatment for brain fog and suggests better sleep habits, regular physical activity, writing important things down, taking short breaks and, where it fits, talking therapy. [5] The Wegovy® Medication Guide asks people to drink fluids to lower the chance of dehydration and to learn from their provider how to recognise and treat low blood sugar if they have type 2 diabetes. [1]
If dizziness or sluggishness comes with a dose increase, the EU guidance on caution with driving is worth following, [2] and the timing is worth noting for your prescriber, who decides how the dose schedule continues.
Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Confusion with seizures or passing out (possible severe low blood sugar) | Emergency services (911 or local number) | Emergency | Canadian patient information [3] |
| Confusion, drowsiness, slurred speech or shakiness if you have type 2 diabetes | Check and treat low blood sugar as agreed; contact your diabetes team | Today | Medication Guide [1] |
| Feeling faint or light-headed with vomiting or diarrhea that does not stop | Your prescriber, promptly | Today | Medication Guide [1] |
| Foggy thinking that disrupts work, conversations or daily tasks | Your primary care provider | At your next appointment | Cleveland Clinic [5] |
